Circulating CD4-positive lymphocyte levels as predictor of response to induction chemotherapy in patients with advanced laryngeal cancer

Head and Neck

Volumn 36, Issue 1, 2014, Pages 9-14

  Dewyer, Nicholas A ^a   Wolf, Gregory T ^a   Light, Emily ^b   Worden, Francis ^b   Urba, Susan ^b   Eisbruch, Avraham ^b   Bradford, Carol R ^a   Chepeha, Douglas B ^a   Prince, Mark E ^a   Moyer, Jeffrey ^a   Taylor, Jeremy ^b  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

chemotherapy; immunity; laryngeal cancer; oropharyngeal cancer; T lymphocytes

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL;

ADVANCED CANCER; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; HUMAN; LARYNX CANCER; LYMPHOCYTE; MAJOR CLINICAL STUDY; OROPHARYNX CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE;

CHEMOTHERAPY; IMMUNITY; LARYNGEAL CANCER; OROPHARYNGEAL CANCER; T LYMPHOCYTES;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LARYNGEAL NEOPLASMS; LARYNGECTOMY; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84890427667     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23263     Document Type: Article

References (14)

1. Urba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 2006; 24: 593-598.
2. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008; 26: 3138-3146.
3. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324: 1685-1690.
4. Pignon JP, Bourhis J, Domenge C, Designé L, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Lancet 2000; 355: 949-955.
5. Wahlin BE, Sundström C, Holte H, et al. T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. Clin Cancer Res 2011; 17: 4136-4144.
6. Hernberg MM, Hahka-Kemppinen MH, Pyrhönen SO,. The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma. Melanoma Res 2004; 14: 493-500.
7. Molling JW, Langius JAE, Langendijk JA, et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 2007; 25: 862-868.
8. Wansom D, Light E, Worden F, et al. Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 2010; 136: 1267-1273.
9. Wolf GT, Bradford CR, Urba S, et al. Immune reactivity does not predict chemotherapy response, organ preservation, or survival in advanced laryngeal cancer. Laryngoscope 2002; 112: 1351-1356.
10. Wolf GT, Schmaltz S, Hudson J, et al. Alterations in T-lymphocyte subpopulations in patients with head and neck cancer. Correlations with prognosis. Arch Otolaryngol Head Neck Surg 1987; 113: 1200-1206.
11. Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I,. The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp 2008; 56: 181-191.
12. Fröhlich M, Sund M, Löwel H, Imhof A, Hoffmeister A, Koenig W,. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003; 24: 1365-1372.
13. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
14. Spanos WC, Nowicki P, Lee DW, et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 2009; 135: 1137-1146.